Prognostic Value of Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR) and Mean Platelet Volume (MPV) In Patients with Colorectal Carcinoma [Izmir Oncology Group(IZOG) Study]

INTRODUCTION: There are various factors that have been determined to affect recurrence and survival in colorectal cancer (CRC). However, few of them exhibit so high a prognostic marker. The present study aimed to investigate the potential of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) as prognostic markers in patients with CRC.
METHODS: We retrospectively examined the demographic and clinical data of 336 patients with colorectal adenocarcinoma in 2008-2014, which recurred after a 12-month follow-up period; the patients had non-metastatic cancer at the time of diagnosis. In order to find out NLR, PLR, and MPV cut-off values, ROC curve analysis was used.
RESULTS: Patients were categorized into two groups according to positive relapse and negative relapse. 89 patients (26.5%) experienced a relapse in the follow-up period. The group NLR≤3.39 had 55.5 months of disease-free survival (p<0.0001) while the group NLR>3.39 had 82.8 months (p<0.0001). The group PLR≤183 had 57.8 months, the group PLR>183 had 78.7 months (p=0.016); the group MPV≤8.3 had 59.7 months, the group MPV>8.3 had 87.2 months; the group MPV>8.3 had 87.2 months and the group MPV<8.3 had 59.7 months (p=0.057).
DISCUSSION AND CONCLUSION: Our study demonstrated that NLR, PLR and MPV levels can actually be relied on as a prognostic factor in patients with CRC. MPV, NLR and PLR values displayed by recently diagnosed patients with CRC may be a reflection of an increased cytokine level and thereby change depending on it.

Nötrofil/Lenfosit Oraný, Trombosit/Lenfosit Oraný ve Ortalama Trombosit Hacminin Kolorektal Karsinomlu Hastalardaki Prognostik Deðeri [Ýzmir Oncoloji Grubu (IZOG) Çalýþmasý]

GÝRÝÞ ve AMAÇ: Önceden kolorektal kanser(KRK) genel saðkalým ve rekürrense etki edebilecek çeþitli faktörler tanýmlanmýþtýr. Ancak bunlarýn birkaçý prognostic marker olarak kabul edilir. Mevcut çalýþmamýzda nötrofil/lenfosit oraný(NLO), trombosit/lenfosit oraný(TLO) ve ortalama trombosit hacminin(OTH) KRK li hastalarada bir biobelirteç olarak potansiyelini araþtýrmayý amaçladýk.
YÖNTEM ve GEREÇLER: Retrospektif olarak taný anýnda metastaik olmayan ve en az 12 aylýk takip periyodu sonrasýnda rekürrens geliþen, 2008-2014 yýllarý arasýnda taný almýþ 336 KRK tanýlý hastanýn klinik ve demografik verilerini incelendik. NLO, TLO ve OTH deðerlerini belirlemek içi ROC eðrisi analizi kullanýldýk.
BULGULAR: Hastalar nüks eden ve etmeyen olarak 2 gruba kategorize edildi. 89 hastada (%26,5) da takip periyodunda nüks geliþti. NLO≤3.39 olan grupta hastalýksýz saðklaým 55.5 bulunurken NLO>3.39 olan grupta hastalýksýz saðkalým 82.8 ay bulundu(p<0.0001). TLO≤183 olan grupta hastalýksýz saðklaým 57.8 ay bulunurken TLO>183 olan grupta ise hastalýksýz saðkalým 78.7 ay bulundu(p: 0.016). OTH≤8.3 olan grupta hastalýksýz saðkalým 59.7 ay bulunurken OTH>8.3 olan grupta ise hastalýksýz saðklaým 59.7 ay oarak bulundu(p: 0.057)
TARTIÞMA ve SONUÇ: Bizim çalýþmamýz NLO,TLO ve OTH seviyelerinin KRK tanýlý hastalarda güvenilebilecek prognostic biyobelirteçler olabileceðini göstermiþtir. Yeni taný almýþ KRK Tanýlý hastalardaki NLO,TLO ve OTH deðerlerinin artan sitokin seviyesini ve buna baðlý olarak deðiþimleri yansýmasý olabilir.